1. de Jong JC, Claas EC, Osterhaus AD, Webster RG, Lim WL. A pandemic warning? Nature. 1997; 389:554.
Article
2. Wu H, Peng X, Xu L, et al. Novel reassortant influenza A (H5N8) viruses in domestic ducks, eastern China. Emerg Infect Dis. 2014; 20:1315–1318.
Article
3. Jeong J, Kang HM, Lee EK, et al. Highly pathogenic avian influenza virus (H5N8) in domestic poultry and its relationship with migratory birds in South Korea during 2014. Vet Microbiol. 2014; 173:249–257.
Article
4. Park SJ, Si YJ, Kim J, et al. Cross-protective efficacies of highly-pathogenic avian influenza H5N1 vaccines against a recent H5N8 virus. Virology. 2016; 498:36–43.
Article
5. Zeng X, Chen P, Liu L, et al. Protective efficacy of an H5N1 inactivated vaccine against challenge with lethal H5N1, H5N2, H5N6, and H5N8 influenza viruses in chickens. Avian Dis. 2016; 60:1 Suppl. 253–255.
Article
6. Steensels M, Rauw F, van den Berg T, et al. Protection afforded by a recombinant Turkey herpesvirus-H5 vaccine against the 2014 European highly pathogenic H5N8 avian influenza strain. Avian Dis. 2016; 60:1 Suppl. 202–209.
Article
7. Krammer F, Palese P. Advances in the development of influenza virus vaccines. Nat Rev Drug Discov. 2015; 14:167–182.
Article
8. Erlewyn-Lajeunesse M, Brathwaite N, Lucas JS, Warner JO. Recommendations for the administration of influenza vaccine in children allergic to egg. BMJ. 2009; 339:b3680.
Article
9. Chroboczek J, Szurgot I, Szolajska E. Virus-like particles as vaccine. Acta Biochim Pol. 2014; 61:531–539.
Article
10. Thompson CM, Petiot E, Lennaertz A, Henry O, Kamen AA. Analytical technologies for influenza virus-like particle candidate vaccines: challenges and emerging approaches. Virol J. 2013; 10:141.
Article
11. Roldao A, Mellado MC, Castilho LR, Carrondo MJ, Alves PM. Virus-like particles in vaccine development. Expert Rev Vaccines. 2010; 9:1149–1176.
Article
12. Singh M, Chakrapani A, O'Hagan D. Nanoparticles and microparticles as vaccine-delivery systems. Expert Rev Vaccines. 2007; 6:797–808.
Article
13. Pushko P, Tumpey TM, Bu F, Knell J, Robinson R, Smith G. Influenza virus-like particles comprised of the HA, NA, and M1 proteins of H9N2 influenza virus induce protective immune responses in BALB/c mice. Vaccine. 2005; 23:5751–5759.
Article
14. Krauss S, Stallknecht DE, Slemons RD, et al. The enigma of the apparent disappearance of Eurasian highly pathogenic H5 clade 2.3.4.4 influenza A viruses in North American waterfowl. Proc Natl Acad Sci U S A. 2016; 113:9033–9038.
15. Lee DH, Sharshov K, Swayne DE, et al. Novel reassortant clade 2.3.4.4 avian influenza A(H5N8) virus in wild aquatic birds, Russia, 2016. Emerg Infect Dis. 2017; 23:359–360.
16. Verhagen JH, Herfst S, Fouchier RA. Infectious disease. How a virus travels the world. Science. 2015; 347:616–617.
Article
17. Ren Z, Ji X, Meng L, et al. H5N1 influenza virus-like particle vaccine protects mice from heterologous virus challenge better than whole inactivated virus. Virus Res. 2015; 200:9–18.
Article